Weight Loss Drugs and Hair Loss: What the Research Says so far

If you've started Ozempic or a similar weight loss medication and noticed more hair on your brush or in the shower drain, you're far from alone. Hair thinning is now one of the most widely reported side effects of GLP-1 medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), and the research linking the two is growing quickly. At Tammy Lobato Wigs, we are now seeing at least one client per week who is affected by weight loss as a result of these drugs and we know how personal and unsettling hair changes can be, so we've pulled together what the research says, what it doesn't yet say, and what you can do about it.

A growing body of evidence

A large study published in the British Medical Journal in July 2026 looked at the health records of around 50,000 adults with type 2 diabetes. People taking GLP-1 medications had a higher chance of hair loss than people taking other diabetes drugs, with one comparison showing a 68% higher risk. Importantly, the researchers found the increase related to non-scarring alopecia, meaning the hair follicles are still intact and regrowth is possible. They also stressed that the absolute risk remained low.

Other research points the same way. A review of randomised controlled trials found hair loss was reported far more often among semaglutide users than comparison groups (roughly 191 cases among about 11,500 users, versus 36 among about 9,800 comparators), although the authors rated the certainty of this evidence as low. A US study of nearly 550,000 adults on GLP-1 medications also suggested an increased risk of certain types of hair loss, particularly telogen effluvium and androgenetic alopecia.

It isn't only research papers, either. Regulators are paying attention too. UK authorities have reportedly received more than 1,200 reports of hair loss linked to semaglutide and tirzepatide since last year, more than 1,000 spontaneous cases have been logged in the US FDA's adverse event database, and the FDA has said it is evaluating hair loss as a potential safety signal. Reports like these can't prove the drugs are responsible, but a steady rise in reports alongside multiple studies is why the link is getting harder to dismiss.

So is it the drug, or the weight loss?

This is the big unanswered question. Most of the studies are observational, which means they can show an association but can't prove that the medication itself causes the hair loss. The BMJ authors suggested the most likely explanation is rapid weight loss, with the reduced food intake that comes with it.

That fits with what we know about hair biology. Significant weight loss from any cause, including diet, bariatric surgery or illness, can push more hair follicles than usual into the resting phase, leading to heavy shedding a few months later. This is called telogen effluvium. Eating much less can also reduce nutrients that hair relies on, such as iron, zinc and protein.

Semaglutide and tirzepatide are among the most effective drugs for weight loss, so it makes sense that they show the strongest signals. Some clinicians also note that hair loss tends to be more common at the higher doses used for obesity than at the lower doses used for diabetes. Still, a few dermatologists report seeing hair changes in people who haven't lost much weight at all, so a single explanation may not tell the whole story.

The Australian perspective

We couldn't find a major peer-reviewed study on this topic conducted in Australia, but local experts are weighing in. Professor Rod Sinclair, an Australian dermatologist with a long-standing focus on hair loss, has told the medical press that it's hard to separate how much of the shedding is caused by the weight loss and how much by the medication.

He has also raised a further concern: that the shedding may not always be a short-lived, self-correcting event. In people who are genetically susceptible, telogen effluvium might unmask or trigger pattern hair loss (androgenetic alopecia). He points out that the two conditions can exist together. For example, a woman might shed after significant weight loss while also having underlying female-pattern thinning that was previously less noticeable. Whether this is happening with GLP-1 medications is still to be properly studied.

Is it permanent?

For most people, hair shedding linked to rapid weight loss is temporary and improves as weight and nutrition stabilise. Treatments such as topical minoxidil may help support regrowth. The less certain scenario is the one described above, where shedding reveals an underlying tendency to pattern hair loss. If your thinning continues well beyond the first several months, it's worth having it assessed.

What can you do?

  • Don't stop your medication on your own. Doctors emphasise that these drugs offer significant benefits for diabetes and obesity. Raise any hair concerns with your prescriber first.
  • Look after your nutrition. Aim for enough protein and make sure you're not eating too little. Avoiding very rapid weight loss and extreme calorie restriction where possible is part of the advice dermatologists give.
  • Ask about bloodwork. Checking iron levels, thyroid function and other nutritional markers can help rule out other contributors.
  • See a GP or dermatologist if shedding is heavy, patchy, or lasts longer than expected. They can work out which type of hair loss you're dealing with.
  • Explore your options while your hair recovers. Hair loss can hit confidence and mood hard, even when it's temporary. A wig or topper can help you feel like yourself in the meantime, and you don't have to figure it out alone.

How we can help

If hair changes are affecting how you feel, our team is here to talk it through. We offer private consultations at our studios in Melbourne, Sydney and Brisbane, and you can book through tammylobatowigs.com.au. We'd always encourage you to speak with your doctor about the cause of your hair loss, and we're happy to support you with the confidence side of things.

The bottom line

Hair loss is increasingly being linked to GLP-1 medications. Multiple large studies, trial analyses and regulator reports now point in the same direction, mostly to the temporary, non-scarring kind. The signal is strongest for semaglutide and tirzepatide, the most powerful weight loss drugs, and weaker or absent for liraglutide and dulaglutide. Rapid weight loss is the leading explanation, but researchers are still working out whether the drugs have an additional effect of their own. For most people the shedding settles, and there are sensible steps to reduce the risk and manage it.

This article is general information only and isn't medical advice. Talk to your doctor about your individual circumstances.

Sources and further reading

  • BMJ cohort study on GLP-1 receptor agonists and hair loss (July 2026)
  • Systematic review and meta-analysis of randomised controlled trials: cutaneous adverse events with semaglutide (PubMed Central)
  • Alopecia as an emerging adverse effect of GLP-1 receptor agonists for weight loss: a scoping review (Cureus, 2025)
  • 2026 systematic review of hair loss across GLP-1 receptor agonists, including liraglutide, dulaglutide and tirzepatide (SAGE journals)
  • Large US TriNetX cohort comparing semaglutide, tirzepatide, dulaglutide and liraglutide with metformin, as summarised by CED Clinic
  • Sodhi et al., risk of hair loss with semaglutide versus bupropion-naltrexone (medRxiv preprint)
  • Survey of hair shedding among GLP-1 users in Saudi Arabia (PubMed Central)
  • TriNetX cohort study of GLP-1 receptor agonists and non-scarring hair loss, as reported by The Medical Republic
  • Professor Rod Sinclair's commentary in The Medical Republic and Dermatology Republic; Sinclair et al., Clinical and Experimental Dermatology (August 2025)
  • Therapeutic Goods Administration, Database of Adverse Event Notifications
  • Reports of hair loss to UK and US regulators, as covered by Eastern Eye and LBC